Development of vaccines for novel severe acute respiratory disease: (Covid-19)


The current threat of avian influenza to the human population, the potential for the re-emergence of severe acute respiratory syndrome (SARS)-associated corona virus, and the identification of multiple novel respiratory viruses underline the need for the event of therapeutic and preventive strategies to combat virus infection. Vaccine development may be a key component within the prevention of widespread virus infection and within the reduction of morbidity and mortality related to many viral infections. In this part, corona virus vaccine, especially SARS-CoV vaccines are mainly discussed.

Corona virus vaccines can be inactivated corona virus, live attenuated corona virus, or S protein-based. Besides, there are still vectored vaccines, DNA vaccines, and combination vaccines against corona viruses. Vaccines targeting several animal CoVs are developed, and a few are demonstrated to be efficacious in preventing virus infection. However, a phenomenon of enhanced disease following vaccination has been observed in cats upon infection with feline infectious peritonitis virus following previous infection, vaccination, or passive transfer of antibody. The phenomenon isn't fully understood but is believed to be a results of enhanced uptake and spread of the virus through binding of virus-antibody immune complexes to Fc receptors on the surfaces of macrophages; low-titter (sub neutralizing) antibodies directed against the S protein are mainly responsible. Although antibody enhancement appears to be limited to feline infectious peritonitis virus among CoVs, similar concerns are raised with reference to SARS-CoV. Previously infected mice and hamsters are shielded from subsequent infection with SARS-CoV within the absence of enhanced disease, and vaccine studies and passive immunoprophylaxis performed with mice and hamsters suggest that previous exposure and the presence of NAbs provide protection.

The virus that causes COVID-19 is mainly transmitted through droplets generated when an infected person coughs, sneezes, or exhales. These droplets are too heavy to hang in the air, and quickly fall on floors or surfaces.

You can be infected by breathing in the virus if you are within close proximity of someone who has COVID-19, or by touching a contaminated surface and then your eyes, nose or mouth.


The immunogenicity and efficacy of inactivated SARS-CoV vaccines are established in experimental animals, and one such vaccine is being evaluated during a clinical test . However, the development of inactivated vaccines requires the propagation of high titters of infectious virus, which in the case of SARS-CoV requires bio safety level 3-enhanced precautions and is a safety concern for production. Additionally, incomplete inactivation of the vaccine virus presents a possible public health threat. Production workers are in danger for infection during handling of concentrated live SARS-CoV, incomplete virus inactivationmay cause SARS outbreaks among the vaccinated populations, and a few viral proteins may induce harmful immune or inflammatory responses, even causing SARS-like diseases

 Open access planning to release a year end special issue has announced almost 50% discount on article publication charges to celebrate its journey for publishing articles with in the short time.

 A standard editorial manager system is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing.

Manuscripts can be forwarded to the Editorial Office at

How we work:

  • After submission, an acknowledgement with manuscript number is sent to the corresponding author within 7 working days.
  • A 21 day window time frame is allotted for peer-review process wherein multiple experts are contacted.
  • Author proof is generated within 7 working days after the acceptance decision.

Benefits on Publication:

Open Access: Permanent free access to your article upon publication ensures extensive global reach and readership.

Easy Article Sharing: Our open access enables you to share your article directly with colleagues through email and on social media via a single link, permitting third party reuse with appropriate citation in addition to the retention of content copyright by the author.

Global Marketing: Through promotion in a targeted global email announcement or press release, your article will be seen by thousands of the top-most thought-leaders in your field.

Color Art: In a world of black & white journal articles, high-quality full-color images make your article stand out from the crowd and tell a complete story, increasing readers and citations.

Social Media Exposure: Extended reach for your article through links on Twitter accounts provides maximum visibility worldwide.

Reprints: Distribute your work to colleagues and at conferences as we provide hard copy color reprints of your article on order.


Media Contact:
John Kimberly
Editorial Manager
Journal of Vaccines & Vaccination
Whatsapp: +44-1470-490003